Home page
MyAlcon for Consumers

My Alcon | United Kingdom

This page is available in English. Select below for other locations.

Select Another Location

Unlock First-Line Glaucoma Care with DSLT5

DSLT is designed to automatically deliver 120 laser pulses directly through the limbus to the trabecular meshwork to improve aqueous outflow and reduce intraocular pressure.5,6

Empty pixel

Introducing DSLT

Icon of an eye dropper above a droplet, crossed out with a diagonal line inside a circle
Icon of an eye dropper above a droplet, crossed out with a diagonal line inside a circle

 

Evolving first-line treatment paradigm2,3,4
Icon of a large downward arrow with four smaller arrows pointing inward, all enclosed in a circular outline
Icon of a large downward arrow with four smaller arrows pointing inward, all enclosed in a circular outline

 

Effective IOP lowering with a proven safety profile5
Icon of two upward arrows, a diagonal line, and a circle arranged in a grid-like pattern
Icon of two upward arrows, a diagonal line, and a circle arranged in a grid-like pattern

 

Simplified workflow for an efficient practice5,6
Icon of an outlined star with a checkmark inside
Icon of an outlined star with a checkmark inside

 

Exceptional experience for the patient and physician6
Three-panel image of the DSLT glaucoma treatment device. Left and right panels show the front of the machine with a circular lens and chin rest. Center panel shows the touchscreen interface with options like 'Start Treatment,' 'Patient List,' and 'Settings.' Text overlays read: 'Comfortable, Gonio-Free Experience,' 'Intuitive Touch Screen, Automatic Target Definition,' and 'Precise Delivery.'

Evolving First-Line Treatment Paradigm

 

The Laser in Glaucoma and Ocular Hypertension (LiGHT) study found that SLT is efficacious as a primary procedure for the treatment of OAG and OHT.1

official logo for American Academy of Ophthalmology
official logo for American Academy of Ophthalmology

 

Recognizes SLT as an effective primary intervention for OAG2

official logo for EGS, European Glaucoma Society
official logo for EGS, European Glaucoma Society

 

Recommends that SLT should be considered as an initial treatment option for mild or moderate OAG and OHT patients3

official logo for NICE, National Institute for Health and Care Excellence
official logo for NICE, National Institute for Health and Care Excellence

 

Recommends 360o SLT as first-line treatment for people with newly diagnosed OHT and COAG4

Exceptional Experience for the Patient and Physician6

“Using the DSLT is awesome. It’s really a step ahead - not only for the comfort of the patient, but also efficiency.”

Univ. -Prof. Dr. med. Burkhard Dick Bochum University Eye Hospital

Introducing DSLT

Effective IOP-Lowering with a Proven Safety Profile5

Direct Selective Laser Trabeculoplasty (DSLT) in Open Angle Glaucoma (OAG)
and Ocular Hypertension (OHT): A Randomized Controlled Trial (GLAUrious)5

Chart comparing intraocular pressure (IOP) reduction from baseline to screening over 12 months for DSLT and SLT treatments. At 6 months (washout period), DSLT shows a reduction of -5.5 mmHg and SLT shows -6.2 mmHg. At 12 months (non-washout), both show a reduction of -3.2 mmHg. A horizontal arrow above the chart marks the 6- and 12-month periods.

Decreased Medication Burden

 

At 12 months5:

62%

of all DSLT patients were medication-free

 

70%

of DSLT patients who entered the study medication-free, remained medication-free

 

81%

of DSLT patients were on the same or fewer medications

 

Proven Safety Profile with Low Rate of Ocular Adverse Events

 

In DSLT group5:

0

No serious AEs as a result of the procedure through 12 months

 

1.0%

Extremely low rate of SSIs for IOP control at 12 months

 

6.1%

Low rate of non-serious AEs at >6 months

 

DSLT Resources

2022 Journal of Glaucoma

 

 

Energy Dose-Response in Selective Laser Trabeculoplasty: A Review

 

Radcliffe N, et al.

 

Read More

 

 

2021 TVST – ARVO Journal

 

 

Automated Direct Selective Laser Trabeculoplasty: First Prospective Clinical Trial

 

Goldenfeld M, et al.

 

Read More

 

 

2021 British Journal of Ophthalmology

 

 

Direct selective laser trabeculoplasty in open angle glaucoma study design

 

Congdon N, et al.

 

Read More

 

 

REFERENCES:

1. Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Laser in Glaucoma and Ocular Hypertension (LiGHT) Trial: Six-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. 2023;130(2):139-151.

2. Takusagawa HL, Hoguet A, Sit AJ, et al. Selective laser trabeculoplasty for the treatment of glaucoma. Ophthalmology. 2024;131(1):37-47. doi:10.1016/j.ophtha.2023.07.029.

3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br J Ophthalmol. 2021;105(Suppl 1):1-169. doi:10.1136/bjophthalmol-2021-egsguidelines.

4. National Institute for Health and Care Excellence. Glaucoma: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2022.

5. GLAUrious Study - Clinical Study Report (CSR). CA-RP-01-006, Rev. 01; 2022.

6. Belkin Vision Eagle Device User Guide, EU. Rev. 7.2; 2024.

 

Please refer to the relevant product direction for use for list of indications, contraindications and warnings.

© 2025 Alcon Inc. 05/25 GB-DLT-2500001